Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 467

The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.

Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets

Open access
Gong, Yue, Ji, Peng, Yang, Yun-Song, Xie, Shao, Yu, Tian-Jian, Xiao, Yi, Jin, Ming-Liang, Ma, Ding, Guo, Lin-Wei, Pei, Yu-Chen, Chai, Wen-Jun, Li, Da-Qiang, Bai, Fan, Bertucci, François, Hu, Xin, Jiang, Yi-Zhou, Shao, Zhi-Ming·2021·Cell Metabolism

Abstract

Triple-negative breast cancer (TNBC) remains an unmet medical challenge. We investigated metabolic dysregulation in TNBCs by using our multi-omics database (n = 465, the largest to date). TNBC samples were classified into three heterogeneous metabolic-pathway-based subtypes (MPSs) with distinct metabolic features: MPS1, the lipogenic subtype with upregulated lipid metabolism; MPS2, the glycolytic subtype with upregulated carbohydrate and nucleotide metabolism; and MPS3, the mixed subtype with partial pathway dysregulation. These subtypes were validated by metabolomic profiling of 72 samples. These three subtypes had distinct prognoses, molecular subtype distributions, and genomic alterations. Moreover, MPS1 TNBCs were more sensitive to metabolic inhibitors targeting fatty acid synthesis, whereas MPS2 TNBCs showed higher sensitivity to inhibitors targeting glycolysis. Importantly, inhibition of lactate dehydrogenase could enhance tumor response to anti-PD-1 immunotherapy in MPS2 TNBCs. Collectively, our analysis demonstrated the metabolic heterogeneity of TNBCs and enabled the development of personalized therapies targeting unique tumor metabolic profiles.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cmet.2020.10.012

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 76 references

Cited by

See all 467

Metadata

Authors
Gong, Y., Ji, P., Yang, Y.-S., Xie, S., Yu, T.-J., Xiao, Y., Jin, M.-L., Ma, D., Guo, L.-W., Pei, Y.-C., Chai, W.-J., Li, D.-Q., Bai, F., Bertucci, F., Hu, X., Jiang, Y.-Z., & Shao, Z.-M.
Venue
Cell Metabolism
Publisher
Elsevier BV
Published
2021-01
Volume
33
Issue
1
Pages
51-64.e9
ISSN
1550-4131 (ISSN-L)
OpenAlex
W3101436145
Cited by
467
References
76
FWCI
16.04
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets. https://app.cochat.ai/papers/10.1016/j.cmet.2020.10.012
The paper
Gong, Y., Ji, P., Yang, Y.-S., Xie, S., Yu, T.-J., Xiao, Y., Jin, M.-L., Ma, D., Guo, L.-W., Pei, Y.-C., Chai, W.-J., Li, D.-Q., Bai, F., Bertucci, F., Hu, X., Jiang, Y.-Z., & Shao, Z.-M. (2021). Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets. Cell Metabolism. https://doi.org/10.1016/j.cmet.2020.10.012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.